Log in

NASDAQ:SRNESorrento Therapeutics Stock Price, Forecast & News

+0.81 (+5.95 %)
(As of 08/7/2020 04:00 PM ET)
Today's Range
Now: $14.42
50-Day Range
MA: $7.44
52-Week Range
Now: $14.42
Volume62.13 million shs
Average Volume22.80 million shs
Market Capitalization$3.49 billion
P/E RatioN/A
Dividend YieldN/A
Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. It offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. The company also develops CD38 Directed chimeric antigen receptor T-cell therapy (CAR-T) for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases; carcinoembryonic antigen CAR-T cell therapy for the treatment of liver metastases of pancreatic cancer; and various human antibodies. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.
Read More
Sorrento Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.45 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:SRNE



Sales & Book Value

Annual Sales$31.43 million
Book Value$0.20 per share


Net Income$-292,070,000.00
Net Margins-754.90%


Market Cap$3.49 billion
Next Earnings Date8/14/2020 (Estimated)
+0.81 (+5.95 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SRNE News and Ratings via Email

Sign-up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Sorrento Therapeutics (NASDAQ:SRNE) Frequently Asked Questions

How has Sorrento Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Sorrento Therapeutics' stock was trading at $1.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SRNE stock has increased by 679.5% and is now trading at $14.42.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of Sorrento Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sorrento Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Sorrento Therapeutics

When is Sorrento Therapeutics' next earnings date?

Sorrento Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020.
View our earnings forecast for Sorrento Therapeutics

How were Sorrento Therapeutics' earnings last quarter?

Sorrento Therapeutics Inc (NASDAQ:SRNE) issued its quarterly earnings data on Monday, May, 11th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.20) by $0.06. The biopharmaceutical company earned $7.72 million during the quarter, compared to analysts' expectations of $10 million. Sorrento Therapeutics had a negative return on equity of 576.10% and a negative net margin of 754.90%.
View Sorrento Therapeutics' earnings history

What price target have analysts set for SRNE?

3 brokers have issued 12-month price objectives for Sorrento Therapeutics' shares. Their forecasts range from $21.00 to $30.00. On average, they expect Sorrento Therapeutics' stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 73.4% from the stock's current price.
View analysts' price targets for Sorrento Therapeutics

Has Sorrento Therapeutics been receiving favorable news coverage?

News coverage about SRNE stock has been trending very positive recently, InfoTrie reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Sorrento Therapeutics earned a daily sentiment score of 4.0 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days.
View the latest news about Sorrento Therapeutics

Who are some of Sorrento Therapeutics' key competitors?

What other stocks do shareholders of Sorrento Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sorrento Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), Novavax (NVAX), Amarin (AMRN), Micron Technology (MU), AbbVie (ABBV) and Opko Health (OPK).

Who are Sorrento Therapeutics' key executives?

Sorrento Therapeutics' management team includes the following people:
  • Dr. Henry H. Ji, Co-Founder, Chairman, CEO & Pres (Age 55)
  • Dr. Jerome Bernard Zeldis, Chief Medical Officer & Pres of Clinical Devel. (Age 69)
  • Mr. George K. Ng, Corp. Sec. (Age 45)
  • Mr. Jiong Shao M.B.A., CFA, Exec. VP & CFO (Age 51)
  • Ms. Deborah H. Telman, Sr. VP & Gen. Counsel

What is Sorrento Therapeutics' stock symbol?

Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."

Who are Sorrento Therapeutics' major shareholders?

Sorrento Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Swiss National Bank (0.13%), Raymond James & Associates (0.11%), Elephas Investment Management Ltd (0.09%), Hancock Whitney Corp (0.08%), New York State Common Retirement Fund (0.07%) and Coastal Investment Advisors Inc. (0.07%). Company insiders that own Sorrento Therapeutics stock include Abg Management Ltd and Robin L Smith.
View institutional ownership trends for Sorrento Therapeutics

Which major investors are selling Sorrento Therapeutics stock?

SRNE stock was sold by a variety of institutional investors in the last quarter, including Integrated Wealth Concepts LLC, UBS Group AG, Donald L. Hagan LLC, Virtus ETF Advisers LLC, SG Americas Securities LLC, and Rathbone Brothers plc.
View insider buying and selling activity for Sorrento Therapeutics

Which major investors are buying Sorrento Therapeutics stock?

SRNE stock was purchased by a variety of institutional investors in the last quarter, including Swiss National Bank, Raymond James & Associates, Elephas Investment Management Ltd, Hancock Whitney Corp, Coastal Investment Advisors Inc., Rafferty Asset Management LLC, Mutual of America Capital Management LLC, and New York State Common Retirement Fund.
View insider buying and selling activity for Sorrento Therapeutics

How do I buy shares of Sorrento Therapeutics?

Shares of SRNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sorrento Therapeutics' stock price today?

One share of SRNE stock can currently be purchased for approximately $14.42.

How big of a company is Sorrento Therapeutics?

Sorrento Therapeutics has a market capitalization of $3.49 billion and generates $31.43 million in revenue each year. The biopharmaceutical company earns $-292,070,000.00 in net income (profit) each year or ($2.12) on an earnings per share basis. Sorrento Therapeutics employs 382 workers across the globe.

What is Sorrento Therapeutics' official website?

The official website for Sorrento Therapeutics is www.sorrentotherapeutics.com.

How can I contact Sorrento Therapeutics?

Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-203-4100 or via email at [email protected]

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.